Mometasone Furoate Patent Expiration

Mometasone Furoate is Used for treating nasal polyps in adult patients who have had ethmoid sinus surgery using a corticosteroid-eluting (mometasone furoate) implant. It was first introduced by Organon Llc A Sub Of Organon And Co in its drug Elocon on Apr 30, 1987. Other drugs containing Mometasone Furoate are Nasonex, Sinuva, Nasonex 24Hr Allergy, Asmanex Hfa, Asmanex Twisthaler. 18 different companies have introduced drugs containing Mometasone Furoate.


Mometasone Furoate Patents

Given below is the list of patents protecting Mometasone Furoate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Asmanex Hfa US5889015 Use of mometasone furoate for treating lower airway passage and lung diseases Jan 27, 2014

(Expired)

Organon Llc
Asmanex Hfa US5889015

(Pediatric)

Use of mometasone furoate for treating lower airway passage and lung diseases Jul 27, 2014

(Expired)

Organon Llc
Asmanex Hfa US6057307 Use of mometasone furoate for treating airway passage and lung diseases Jan 27, 2014

(Expired)

Organon Llc
Asmanex Hfa US6057307

(Pediatric)

Use of mometasone furoate for treating airway passage and lung diseases Jul 27, 2014

(Expired)

Organon Llc
Asmanex Hfa US6068832 Chlorofluorocarbon-free mometasone furoate aerosol formulations Aug 27, 2017

(Expired)

Organon Llc
Asmanex Hfa US6365581 Use of mometasone furoate for treating airway passage and lung diseases Jan 27, 2014

(Expired)

Organon Llc
Asmanex Hfa US6365581

(Pediatric)

Use of mometasone furoate for treating airway passage and lung diseases Jul 27, 2014

(Expired)

Organon Llc
Asmanex Twisthaler US5394868

(Pediatric)

Inhalation device for powdered medicaments Dec 25, 2012

(Expired)

Organon Llc
Asmanex Twisthaler US5687710 Inhaler for powdered medications having spiral deagglomeration chamber Nov 18, 2014

(Expired)

Organon Llc
Asmanex Twisthaler US5687710

(Pediatric)

Inhaler for powdered medications having spiral deagglomeration chamber May 18, 2015

(Expired)

Organon Llc
Asmanex Twisthaler US5829434 Inhaler for powdered medications Nov 03, 2015

(Expired)

Organon Llc
Asmanex Twisthaler US5829434

(Pediatric)

Inhaler for powdered medications May 03, 2016

(Expired)

Organon Llc
Asmanex Twisthaler US5889015 Use of mometasone furoate for treating lower airway passage and lung diseases Jan 27, 2014

(Expired)

Organon Llc
Asmanex Twisthaler US5889015

(Pediatric)

Use of mometasone furoate for treating lower airway passage and lung diseases Jul 27, 2014

(Expired)

Organon Llc
Asmanex Twisthaler US6057307 Use of mometasone furoate for treating airway passage and lung diseases Jan 27, 2014

(Expired)

Organon Llc
Asmanex Twisthaler US6057307

(Pediatric)

Use of mometasone furoate for treating airway passage and lung diseases Jul 27, 2014

(Expired)

Organon Llc
Asmanex Twisthaler US6240918 Powdered medication inhaler Feb 20, 2017

(Expired)

Organon Llc
Asmanex Twisthaler US6240918

(Pediatric)

Powdered medication inhaler Aug 20, 2017

(Expired)

Organon Llc
Asmanex Twisthaler US6365581 Use of mometasone furoate for treating airway passage and lung diseases Jan 27, 2014

(Expired)

Organon Llc
Asmanex Twisthaler US6365581

(Pediatric)

Use of mometasone furoate for treating airway passage and lung diseases Jul 27, 2014

(Expired)

Organon Llc
Asmanex Twisthaler US6503537 Preparation of powder agglomerates Mar 17, 2018

(Expired)

Organon Llc
Asmanex Twisthaler US6503537

(Pediatric)

Preparation of powder agglomerates Sep 17, 2018

(Expired)

Organon Llc
Asmanex Twisthaler US6677322 Use of mometasone furoate for treating airway passage and lung diseases Jan 27, 2014

(Expired)

Organon Llc
Asmanex Twisthaler US6677322

(Pediatric)

Use of mometasone furoate for treating airway passage and lung diseases Jul 27, 2014

(Expired)

Organon Llc
Asmanex Twisthaler US6949532 Use of mometasone furoate for treating airway passage and lung diseases Jan 27, 2014

(Expired)

Organon Llc
Asmanex Twisthaler US6949532

(Pediatric)

Use of mometasone furoate for treating airway passage and lung diseases Jul 27, 2014

(Expired)

Organon Llc
Asmanex Twisthaler US8173172 Preparation of powder agglomerates Mar 17, 2018

(Expired)

Organon Llc
Asmanex Twisthaler US8173172

(Pediatric)

Preparation of powder agglomerates Sep 17, 2018

(Expired)

Organon Llc
Nasonex US5837699 Use of mometasone furoate for treating upper airway passage diseases Jan 27, 2014

(Expired)

Organon Llc
Nasonex US5837699

(Pediatric)

Use of mometasone furoate for treating upper airway passage diseases Jul 27, 2014

(Expired)

Organon Llc
Nasonex US6127353 Mometasone furoate monohydrate, process for making same and pharmaceutical compositions Oct 03, 2017

(Expired)

Organon Llc
Nasonex US6127353

(Pediatric)

Mometasone furoate monohydrate, process for making same and pharmaceutical compositions Apr 03, 2018

(Expired)

Organon Llc
Nasonex US6723713 Use of mometasone furoate for treating upper airway diseases Jan 27, 2014

(Expired)

Organon Llc
Nasonex US6723713

(Pediatric)

Use of mometasone furoate for treating upper airway diseases Jul 27, 2014

(Expired)

Organon Llc
Sinuva US10232152 Systems, devices, and method for treating a sinus condition Nov 24, 2034 Intersect Ent Inc
Sinuva US10357640 Expandable devices and methods for treating a nasal or sinus condition Oct 03, 2031 Intersect Ent Inc
Sinuva US10406332 Systems, devices, and method for treating a sinus condition Mar 13, 2034 Intersect Ent Inc
Sinuva US7544192 Sinus delivery of sustained release therapeutics Nov 29, 2026 Intersect Ent Inc
Sinuva US7662141 Sinus delivery of sustained release therapeutics Mar 12, 2024

(Expired)

Intersect Ent Inc
Sinuva US7713255 Sinus delivery of sustained release therapeutics Mar 12, 2024

(Expired)

Intersect Ent Inc
Sinuva US7951130 Sinus delivery of sustained release therapeutics Mar 12, 2024

(Expired)

Intersect Ent Inc
Sinuva US7951131 Sinus delivery of sustained release therapeutics Mar 12, 2024

(Expired)

Intersect Ent Inc
Sinuva US7951133 Sinus delivery of sustained release therapeutics Mar 12, 2024

(Expired)

Intersect Ent Inc
Sinuva US8025635 Device and methods for treating paranasal sinus conditions Jun 12, 2027 Intersect Ent Inc
Sinuva US8109918 Sinus delivery of sustained release therapeutics Mar 12, 2024

(Expired)

Intersect Ent Inc
Sinuva US8763222 Methods and devices for crimping self-expanding devices Feb 08, 2032 Intersect Ent Inc
Sinuva US9585681 Device and methods for treating paranasal sinus conditions Apr 04, 2026 Intersect Ent Inc


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Mometasone Furoate's patents.

Given below is the list recent legal activities going on the following patents of Mometasone Furoate.

Event Date Patent/Publication
Patent litigations
Email Notification 12 Apr, 2024 US8109918
Mail O.P. Petition Decision 12 Apr, 2024 US8109918
Mail-Record Petition Decision of Granted to Make Entity Status large 09 Apr, 2024 US8109918
O.P. Petition Decision 08 Apr, 2024 US8109918
Record Petition Decision of Granted to Make Entity Status large 08 Apr, 2024 US8109918
Payment of Maintenance Fee under 1.28(c) 13 Feb, 2024 US8109918
Petition Entered 13 Feb, 2024 US8109918
Entity Status Set To Undiscounted (Initial Default Setting or Status Change) 13 Feb, 2024 US8109918
Change in Power of Attorney (May Include Associate POA) 09 Feb, 2024 US8109918
Email Notification 09 Feb, 2024 US8109918



Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳

Mometasone Furoate Generics

Several generic applications have been filed for Mometasone Furoate. The first generic version for Mometasone Furoate was by Padagis Us Llc and was approved on Mar 18, 2002. And the latest generic version is by Apotex Inc and was approved on Apr 23, 2024.

Given below is the list of companies who have filed for Mometasone Furoate generic.


1. FOUGERA PHARMS

Fougera Pharmaceuticals Inc has filed for 1 generic for Mometasone Furoate. Given below are the details of the strengths of this generic introduced by Fougera Pharms.

Strength Dosage Form Availability Application Pathway TE code Launch Date
0.1% lotion Prescription TOPICAL AB Nov 29, 2007


2. TARO

Taro Pharmaceuticals Inc has filed for 1 generic for Mometasone Furoate. Given below are the details of the strengths of this generic introduced by Taro.

Strength Dosage Form Availability Application Pathway TE code Launch Date
0.1% lotion Prescription TOPICAL AB Mar 15, 2006


3. ENCUBE

Encube Ethicals Private Ltd has filed for 1 generic for Mometasone Furoate. Given below are the details of the strengths of this generic introduced by Encube.

Strength Dosage Form Availability Application Pathway TE code Launch Date
0.1% lotion Discontinued TOPICAL N/A Nov 21, 2007


4. ANDA REPOSITORY

Anda Repository Llc has filed for 1 generic for Mometasone Furoate. Given below are the details of the strengths of this generic introduced by Anda Repository.

Strength Dosage Form Availability Application Pathway TE code Launch Date
0.1% cream Discontinued TOPICAL N/A Apr 18, 2007


5. TORRENT

Torrent Pharmaceuticals Ltd has filed for 1 generic for Mometasone Furoate. Given below are the details of the strengths of this generic introduced by Torrent.

Strength Dosage Form Availability Application Pathway TE code Launch Date
0.1% ointment Discontinued TOPICAL N/A Jul 13, 2018


6. AMNEAL

Amneal Pharmaceuticals Llc has filed for 1 generic for Mometasone Furoate. Given below are the details of the strengths of this generic introduced by Amneal.

Strength Dosage Form Availability Application Pathway TE code Launch Date
0.05MG/SPRAY spray, metered Discontinued NASAL N/A Jun 14, 2023


7. COSETTE

Cosette Pharmaceuticals Inc has filed for 1 generic for Mometasone Furoate. Given below are the details of the strengths of this generic introduced by Cosette.

Strength Dosage Form Availability Application Pathway TE code Launch Date
0.1% lotion Discontinued TOPICAL N/A Nov 21, 2007


8. GLENMARK PHARMS INC

Glenmark Pharmaceuticals Inc Usa has filed for 1 generic for Mometasone Furoate. Given below are the details of the strengths of this generic introduced by Glenmark Pharms Inc.

Strength Dosage Form Availability Application Pathway TE code Launch Date
0.1%

(reference standard)

ointment Prescription TOPICAL AB May 28, 2008


9. AMNEAL PHARMS

Amneal Pharmaceuticals has filed for 1 generic for Mometasone Furoate. Given below are the details of the strengths of this generic introduced by Amneal Pharms.

Strength Dosage Form Availability Application Pathway TE code Launch Date
0.05MG/SPRAY spray, metered Prescription NASAL AB Apr 3, 2017


10. AUROBINDO PHARMA

Aurobindo Pharma Ltd has filed for 1 generic for Mometasone Furoate. Given below are the details of the strengths of this generic introduced by Aurobindo Pharma.

Strength Dosage Form Availability Application Pathway TE code Launch Date
0.05MG/SPRAY spray, metered Prescription NASAL AB Mar 18, 2024


11. PADAGIS US

Padagis Us Llc has filed for 1 generic for Mometasone Furoate. Given below are the details of the strengths of this generic introduced by Padagis Us.

Strength Dosage Form Availability Application Pathway TE code Launch Date
0.1% ointment Prescription TOPICAL AB Mar 18, 2002


12. APOTEX

Apotex Inc has filed for 1 generic for Mometasone Furoate. Given below are the details of the strengths of this generic introduced by Apotex.

Strength Dosage Form Availability Application Pathway TE code Launch Date
0.05MG/SPRAY spray, metered Over the counter NASAL N/A Apr 23, 2024


13. GLENMARK PHARMS LTD

Glenmark Pharmaceuticals Ltd has filed for 1 generic for Mometasone Furoate. Given below are the details of the strengths of this generic introduced by Glenmark Pharms Ltd.

Strength Dosage Form Availability Application Pathway TE code Launch Date
0.1% lotion Prescription TOPICAL AB Aug 9, 2010


14. PADAGIS ISRAEL

Padagis Israel Pharmaceuticals Ltd has filed for 1 generic for Mometasone Furoate. Given below are the details of the strengths of this generic introduced by Padagis Israel.

Strength Dosage Form Availability Application Pathway TE code Launch Date
0.1%

(reference standard)

lotion Prescription TOPICAL AB Apr 6, 2005